Bristol Myers Squibb’s (BMY) and Pfizer’s (PFE) Alliance announced a new direct-to-patient option for purchasing Eliquis – apixaban – via their Alliance’s patient resource Eliquis 360 Support. The offering provides an opportunity for uninsured, underinsured, or self-pay patients to lower their out-of-pocket costs for this medicine. Beginning September 8, eligible U.S. patients with an Eliquis prescription may purchase the medicine directly through Eliquis 360 Support and will pay a discounted rate of more than 40% less than the current list price. The program will provide direct shipping to patients across all 50 states and Puerto Rico.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Morgan Stanley sees Bristol Myers share catalyst on Alzheimer’s data
- Caution on Bristol-Myers Squibb: Reliance on Cobenfy Amid Uncertain Market Potential
- Trump says drug tariffs probable by August 1, semis coming soon, Bloomberg says
- Bristol-Myers Squibb’s Psoriasis Drug Study Update: Key Insights for Investors
- Bristol-Myers Squibb’s KarXT Study: A Potential Game-Changer for Bipolar-I Disorder